Journal: Journal of chemotherapy (Florence, Italy)
This study evaluated the efficacy of GEMOX chemotherapy combined with Tislelizumab versus GEMOX alone in 150 patients with stage III-IV advanced gallbladder cancer.
The combination therapy group demonstrated:
- Significantly improved median overall survival (13.35 vs. 10.26 months)
- Improved progression-free survival (7.28 vs. 5.18 months)
- Higher disease control rate
- Higher objective response rate
Independent prognostic factors for overall survival included:
- TNM stage
- CA19-9 levels
- CPS score
- Tumor size
- Lesion multiplicity
These results suggest that adding Tislelizumab to GEMOX may enhance survival outcomes in advanced gallbladder cancer.